New targets for therapy in breast cancer: farnesyltransferase inhibitors

Related Experiment Video

Updated: Aug 21, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Julia Head1, Stephen R D Johnston

  • 1Department of Medicine, Royal Marsden Hospital, London, UK.

Breast Cancer Research : BCR
|November 13, 2004
PubMed

Insights

Protein farnesyltransferase inhibitors (FTIs) show promise in treating breast cancer by inhibiting cancer cell growth. Combining FTIs with existing therapies like taxanes or tamoxifen may enhance treatment effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Current breast cancer therapies face challenges including drug resistance and toxicity.
  • Targeting specific molecular pathways offers a promising strategy for cancer treatment.
  • Protein farnesyltransferase inhibitors (FTIs) are a class of drugs targeting signal transduction pathways.

Purpose of the Study:

  • To evaluate the efficacy of FTIs as a novel treatment strategy for breast cancer.
  • To investigate the potential synergistic effects of FTIs when combined with conventional breast cancer therapies.
  • To assess the safety and tolerability of FTIs in clinical trials.

Main Methods:

  • Preclinical studies assessed FTI efficacy against various cancer cell lines, including breast cancer.
  • Combination studies explored the additive or synergistic effects of FTIs with cytotoxic agents (taxanes) and endocrine therapies (tamoxifen).
  • Phase I and II clinical trials evaluated FTI safety, dosing, and efficacy in breast cancer patients.

Main Results:

  • FTIs demonstrated potent inhibition of breast cancer cell growth, even in cells without ras mutations.
  • Synergistic effects were observed when FTIs were combined with taxanes and tamoxifen.
  • Phase II trials showed clinical efficacy for the FTI tipifarnib in breast cancer, with dose-limiting toxicities including myelosuppression and neuropathy.

Conclusions:

  • FTIs represent a promising new therapeutic strategy for breast cancer.
  • Combination therapy with FTIs and conventional agents like taxanes or tamoxifen warrants further investigation.
  • Ongoing clinical studies aim to confirm the enhanced efficacy of FTIs in combination breast cancer treatment.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...